A four-step flow diagram illustrating the Cell-Based Immunization and Screening (CBIS) method for monoclonal antibody (mAb) production. Step 1: Immunization of cell lines involves the intraperitoneal injection of tasPDPN-expressing cells into a mouse model. Step 2: Production of hybridomas depicts the fusion of myelomas with splenocytes (B cells) harvested from the immunized mouse. Step 3: Flow cytometric screening shows the differentiation between target tasPDPN-expressing cells and parental cells. Specifically, antibodies (Y-shaped icons) bind to the tasPDPN-expressing cells, while no binding occurs on parental cells, indicated by a dashed arrow and an 'X'. Step 4: Cloning of hybridomas illustrates the isolation and cultivation of specific tasPDPN-specific mAb-producing hybridomas. This methodology highlights a strategy for developing highly specific antibodies against membrane proteins without the need for protein purification, utilizing stable transfectants as immunogens. The illustration is relevant for laboratory techniques in immunology, biotechnology, and diagnostic pathology.

A flow diagram illustrating the experimental workflow for recombinant monoclonal antibody (mAb) production, comparing Fluorescence-Activated Cell Sorting (FACS) and droplet-based microfluidics. The process begins with 'Immunization' of a mouse model, followed by 'B lymphocytes collection' (splenocytes/plasmablasts). The 'Sorting' stage contrasts two high-throughput methods: FACS, which sorts individual cells into multi-well plates for single-cell RT-PCR (scRT-PCR), and droplet-based microfluidics, which encapsulates single cells in aqueous droplets for merger with PCR reagent droplets. The workflow converges at 'Amplicons sequencing,' highlighting the amplification of paired heavy (VH) and light (VL) chain variable regions, illustrated by an antibody diagram and a DNA sequencing chromatogram (A, T, C, G peaks). The final stage is 'Expression cloning,' depicting the integration of sequenced VH and VL genes into expression vectors for mAb production in various systems. This schematic serves as an educational resource for immunology and biotechnology, specifically focusing on single-cell technologies and antibody discovery campaigns.

This medical laboratory diagram illustrates a sandwich Enzyme-Linked Immunosorbent Assay (ELISA) technique used for the detection of VHH (variable heavy-chain antibodies). The schematic depicts the spatial arrangement of the assay components within a microtiter plate well from bottom to top: (a) A capture layer consisting of Rabbit anti-VHH polyclonal antibodies (pAb), which are passively adsorbed to the bottom of the well. (b) The analyte, represented as an HA-tagged VHH molecule, where the VHH core binds to the capture antibody and an HA (hemagglutinin) tag is available for detection. (c) The detection layer featuring an HRP-labeled anti-HA monoclonal antibody (mAb). This antibody targets the HA tag of the analyte and is conjugated to Horseradish Peroxidase (HRP), shown as a purple star-shaped molecule. At the top, a blue curved arrow labeled TMB (3,3′,5,5′-Tetramethylbenzidine) represents the chromogenic substrate added to the well. The diagram demonstrates the biochemical principle of signal transduction where HRP catalyzes the oxidation of TMB to produce a measurable colorimetric signal, indicating the presence and concentration of the VHH analyte.

This pathophysiology diagram outlines the 'Possible mechanisms of action of IVIG' (Intravenous Immunoglobulin). A central Y-shaped antibody model illustrates standard structural components: two blue heavy chains and two orange light chains. The lower portion identifies the constant (Fc) region, while the tips of the Fab arms show the antigen-binding sites. One tip is shown binding to a green antigen at its specific epitope. Surrounding the antibody are three categorical descriptions of IVIG's therapeutic roles: 1) Anti-inflammatory effects, including the reduction of pro-inflammatory cytokines and blocking of leukocyte adhesion molecules (LAM). 2) Anti-viral and bacterial effects, highlighting neutralization of pathogens and toxins, agglutination, and complement system activation. 3) Immunomodulatory effects, emphasizing the stimulation of inhibitory Fc-gamma receptors on macrophages, suppression of B-cell activation to prevent alloimmunization, and blocking of phagocytic Fc receptors. This educational material serves as a conceptual summary for clinical immunology and pharmacology related to immunoglobulin therapy.

This composite educational graphic details the molecular mapping and conformational analysis of beta1 (β1) integrin in Jurkat cells. Panel (a) presents a 3D ribbon diagram of the β1 integrin protein structure, highlighting key functional domains and epitope locations including MIDAS (Metal Ion-Dependent Adhesion Site), ADMIDAS (Adjacent to MIDAS), LIBS (Ligand-Induced Binding Sites), and the binding site for the JB1a antibody. Panels (b) through (e) provide flow cytometry-based FRET (Fluorescence Resonance Energy Transfer) data plots illustrating integrin activation states. The y-axis measures LDV-FITC ligand binding (mean channel fluorescence, MCF) and the x-axis represents time. These plots compare basal activity versus Mn2+-induced activation across different experimental conditions: control (b), and the addition of specific antibodies JB1a (c), K20 (d), and B44 (e). The dense data distributions (heat-mapped from blue to red) visualize how these different clones modulate integrin conformation and ligand affinity, shifting from partially extended to fully active states.